NCT04579380 2025-12-19Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsSeagen Inc.Phase 2 Active not recruiting217 enrolled 19 charts
NCT04464967 2021-05-12Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNKGen Biotech, Inc.Phase 1/2 Withdrawn